Rivaroxaban

Generic Name
Rivaroxaban
Brand Names
Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
Drug Type
Small Molecule
Chemical Formula
C19H18ClN3O5S
CAS Number
366789-02-8
Unique Ingredient Identifier
9NDF7JZ4M3
Background

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...

Indication

Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...

Associated Conditions
Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
Associated Therapies
-
Clinical Trials
Related News

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

First Posted Date
2021-08-26
Last Posted Date
2023-08-03
Lead Sponsor
Pfizer
Target Recruit Count
55759
Registration Number
NCT05022563
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

🇰🇷

Sungkyunkwan University, Suwon-si, Korea, Republic of

Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin

First Posted Date
2021-08-10
Last Posted Date
2021-08-10
Lead Sponsor
André Luiz Malavasi Longo de Oliveira
Target Recruit Count
440
Registration Number
NCT04999176
Locations
🇧🇷

Science Valley Research Institute, Santo André, São Paulo, Brazil

An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)

Not Applicable
Completed
Conditions
Ventricular Mural Thrombosis
Interventions
Drug: Rivaroxaban
First Posted Date
2021-07-21
Last Posted Date
2024-08-02
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
75
Registration Number
NCT04970381
Locations
🇨🇳

Fuwai Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College, Beijing, China

Rivaroxaban in Left Ventricular Thrombus

First Posted Date
2021-07-21
Last Posted Date
2024-11-15
Lead Sponsor
National Institute of Cardiovascular Diseases, Pakistan
Target Recruit Count
261
Registration Number
NCT04970576
Locations
🇵🇰

National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan

Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis

Phase 3
Conditions
Venous Thrombosis
Interventions
Drug: Rivaroxaban
First Posted Date
2021-07-19
Last Posted Date
2022-02-16
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
480
Registration Number
NCT04967573
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, China

🇨🇳

Huadong Hospital affiliated to Fudan University, Shanghai, China

🇨🇳

Shanghai General Hospital, Shanghai, China

and more 1 locations

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

First Posted Date
2021-05-10
Last Posted Date
2023-07-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
98947
Registration Number
NCT04879407
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

First Posted Date
2021-05-07
Last Posted Date
2021-05-07
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
1000000
Registration Number
NCT04878497
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

NOAC Portuguese Real World Study

First Posted Date
2021-03-22
Last Posted Date
2023-04-05
Lead Sponsor
Pfizer
Registration Number
NCT04808934

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

First Posted Date
2021-03-12
Last Posted Date
2024-04-04
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
9
Registration Number
NCT04794569
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

🇨🇦

Hamilton General Hospital, Hamilton, Ontario, Canada

🇨🇦

Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada

and more 2 locations

Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Rivaroxaban
Drug: Activated charcoal
First Posted Date
2021-02-23
Last Posted Date
2022-12-05
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Target Recruit Count
12
Registration Number
NCT04767776
Locations
🇫🇷

CHU de SAINT-ETIENNE, Saint-etienne, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy